Cost-effectiveness of glaucoma management with monotherapy medications in Egypt

Amal Abd-Elaal El-Khamery¹, Amir Ibrahim Mohamed², Hassan Eisa Hassan Swify³, Alaa Ibrahim Mohamed⁴

¹Lecturer and ²Associate Professor, Military Medical Academy, ³Department of Medical services, Consultant eye-surgeon FRCS Ed. Ophthalmology, ⁴Faculty of Pharmacy, Cairo University, Cairo, Egypt

J. Adv. Pharm. Technol. Res.

Abstract

Glaucoma is a serious chronic ophthalmic disease since it causes irreversible visual disability if untreated can lead to blindness. Treatment options include medications (classified into five major classes of drugs which are muscarinic cholinergic agonists, alpha-2 adrenergic agonists, beta-1 adrenergic antagonists, prostaglandins [PGs], and carbonic anhydrase inhibitors); use of laser therapy or conventional surgery. Pharmacoeconomic analysis helps in choosing among this variety of treatments. There is a great need for such analysis in Egypt since undergoing of it in different countries or societies may produce different results. This work aimed to compare cost-effectiveness of bimatoprost 0.03% once daily versus brimonidine 0.2% twice daily and timolol 0.5% twice daily as monotherapy treatment in Egyptian patients with open-angle glaucoma or ocular hypertension. Clinical data revealed that all treatments decreased intraocular pressure (IOP) significantly but bimatoprost 0.03% showed the highest efficacy (27.7% decrease in IOP from baseline), while timolol 0.5% reduced IOP by 22.5% then brimonidine 0.2% which decreased IOP by 20.8%. From the cost-effectiveness view, it would be preferable to initiate treatment with timolol in case of absence of any contraindications. PG analog can be used as add-on therapy in low responder patients or as alternative treatment in case of presence of contraindication to use of beta blockers.

Key words: Cost-effectiveness, glaucoma, pharmacoeconomic analysis

INTRODUCTION

Glaucoma is a condition of the eye in which there an increase in the intraocular pressure (IOP), causing progressive atrophy of the optic nerve with deterioration of vision and if untreated, blindness. The higher the IOP, the greater the risk of optic nerve damage, visual loss, and blindness. Early, pressure-lowering treatment is a dominant cost-effective treatment strategy or a strategy to start the same treatment approach later, after glaucoma has occurred for patients with ocular hypertension.

Address for correspondence:
Dr. Amal Abd-Elaal El-Khamery, Military Medical Academy, Cairo, Egypt.
E-mail: amal_k71@yahoo.com

Treatment options of glaucoma include medical treatment, laser therapy, and incisional surgery. The major classes of drugs for glaucoma treatment are muscarinic cholinergic agonists, alpha-2 adrenergic agonists which acts to reduce aqueous humor production and increase the outflow of aqueous humor, carbonic anhydrase inhibitors that acts by inhibition of carbonic anhydrase in the eye so decreases aqueous humor secretion, resulting in a decrease of IOP, beta-1 adrenergic antagonists. The advantages of beta-blockers are good efficacy in primary and secondary types of glaucoma, easy use in combination with all other glaucoma drugs, and low costs. Timolol is the most frequently used drug in fixed glaucoma medications. In comparison with other glaucoma...
drugs, beta-blockers have the most severe systemic side effects and may interact with other systemic medication,[5,6] and prostaglandin (PG) analogs that are highly efficient in lowering the IOP. In particular, they appear to have a good control of 24 h IOP fluctuations by primarily improving the outflow pathways. Furthermore, they have less systemic side effects than beta-blockers. However, their use is often associated with higher costs.[7]

Cost-effectiveness analysis (CEA) is used to compare medications that have different costs and quantitatively different outcomes with the latter expressed in the same natural units.[8]

Scope of work
The objective of this study was to perform a CEA between different drugs used as a single first-line treatment of glaucoma.

PATIENTS AND METHODS

Patients
Inclusion criteria were adult patients (>18 years), diagnosis of ocular hypertension or glaucoma (i.e., IOP ≥22 and ≤34). Exclusion criteria were pregnant or nursing females, any conditions or medication that would put the patient at risk or interfere with study results, any sensitivity or contraindication to medication used.

Drug products
- Lumigan™ (bimatoprost 0.03%): Manufactured by Allergan, USA. Marketed in Egypt by Sofico Company, Batch No. 1399
- Timolol (timolol maleat 0.5%): Manufactured by Nile Co., for Pharmaceuticals and Chemical Industries, Egypt. Batch No. 912418
- Brimonidine (brimonidine tartrate 0.2%): Manufactured by Jamjoom Pharmaceuticals, Saudi Arabia. Marketed in Egypt by Malty Pharma Company Batch No. PL 0118.

Equipment
- Haag-Streit 900 series slit lamp +78D lens (Japan)
- Applanation Tonometer 900AT® which is a powerful accessory to the Haag-Streit 900 series slit lamps for measurement of IOP (Japan)
- Humphrey visual field (VF) 740i analyzer (USA).

Methodology

Clinical examination of study patients
Physician saw the patient (long visit) at baseline and patient assigned to monotherapy treatment. All patients undergo an established follow-up visit (short visit) 1 month after baseline. The second short visit was 3 months after initiation of monotherapy treatment to determine tolerability and initial response. If patient achieved lower IOP, he/she would remain on the assigned monotherapy treatment, and the next visit would be at month 9. Patients showed intolerability or lack of response at month 3 excluded from the study and shifted to another treatment or adjunctive treatment was prescribed. Treatment algorithm was shown in Figure 1.

Treatment protocol
- Lumigan™ (bimatoprost 0.03%) one drop was administered once daily in the evening in the first group
- Timolol (timolol maleat 0.5%): One drop was administered twice daily in the second group
- Brimonidine (brimonidine tartrate 0.2%): One drop was administered twice daily in the third group.[8]

Statistical analysis of data
Statistical analysis was carried out using SPSS program software version 11 (Echo Soft Corp., USA).

Paired t-test for comparison between each two dependent groups (before and after administration of treatment) was conducted to test the significance for each measured parameter.

One-way ANOVA test was conducted to test the significance between parallel groups for measured parameter before administration data. The same was done for parallel group after administration data.

P ≤ 0.05 was considered as a criterion of significance.

Table 1: Clinical effect of treatment administration

| Item               | Before          | After           | Significance |
|--------------------|-----------------|-----------------|--------------|
| Bimatoprost (Lumigan) | 25.20±0.39      | 18.22±0.28      | Sig          |
| Timolol (Timolol)    | 25.03±0.57      | 19.40±0.48      | Sig          |
| Brimonidine (Brimonidine) | 25.09±0.58     | 19.87±1.02      | Sig          |

This table shows that IOP level significantly decreased in all groups after administration of glaucoma medication

Figure 1: Treatment algorithm of patients undergoing the clinical study. IOP: Intraocular pressure
RESULTS

Clinical results are summarized in Tables 1-4. Clinical effect of treatment administration on mean IOP is shown in Table 1. For testing presence of a significant difference between parallel groups, one-way ANOVA is used; data of before administration of treatment is represented in Table 2 while data of after administration of treatment is represented in Tables 3 and 4.

PHARMACOECONOMIC COMPARISON BETWEEN TREATMENTS

A CEA was performed. Only direct medical costs were considered in the present pharmacoeconomic analysis between bimatoprost and timolol and brimonidine.

Table 2: One-way ANOVA before treatment

| Source of variation | SS     | df | MS     | F       | P       | F crit | Significance |
|---------------------|--------|----|--------|---------|---------|--------|--------------|
| Between Groups      | 0.294333 | 2  | 0.147167 | 0.285663 | 0.752585 | 3.158843 | Non-sig      |
| Within Groups       | 29.365 | 57 | 0.515175 |         |         |        |              |
| Total               | 29.65933 | 59 |        |         |         |        |              |

This table shows No significant difference could be determined when comparing parallel groups data before administration of treatment.

Table 3: One-way ANOVA after treatment

| Source of variation | SS     | df | MS     | F       | P       | F crit | Significance |
|---------------------|--------|----|--------|---------|---------|--------|--------------|
| Between Groups      | 29.09433 | 2  | 14.54717 | 24.59953 | 1.99E-08 | 3.158843 | Sig          |
| Within Groups       | 33.7075 | 57 | 0.59136 |         |         |        |              |
| Total               | 62.80183 | 59 |        |         |         |        |              |

This table reveals significant difference could be determined upon comparing parallel group data after administration of treatment.

Table 4: Significance of clinical effect difference between groups after treatment administration

| Item                     | Variable 1 | Variable 2 | Significance |
|--------------------------|------------|------------|--------------|
| Bimatoprost vs. Timolol  | 18.22±0.28 | 19.40±0.48 | Sig          |
| Bimatoprost vs. Brimondin| 18.22±0.28 | 19.87±1.02 | Sig          |
| Timolol vs. Brimondin    | 19.40±0.48 | 19.87±1.02 | Non-Sig      |

This table reveals that Bimatoprost significantly decrease IOP when compared with Timolol or Brimondin while no significant difference could be determined upon comparing Timolol and Brimondin.

Table 5: Cost-effectiveness ratio of the interventions

| Groups     | Cost/patient (L.E) | Total cost (cost of all patients) (L.E) | Effectiveness (% reduction in IOP) | ACER* |
|------------|--------------------|----------------------------------------|-----------------------------------|-------|
| Bimatoprost| 3480               | 69600                                  | 27.7                              | 2512.64 |
| Timolol    | 1716               | 34320                                  | 22.5                              | 1525.33 |
| Brimondin  | 4470               | 89400                                  | 20.8                              | 4298.08 |

*ACER: Average cost effectiveness ratio. This table revealed that Timolol was the dominant treatment intervention.

Costs

The costs of medical resources were assigned in Egyptian pounds (year 2013–2014 values). Costs for patient care and physician services were based on Egyptian Medicare reimbursement rates. In this study, the cost assessment was done for each patient by calculating the total costs paid per patient.

Effectiveness

Efficacy of treatment was defined as “percentage reduction in IOP compared with baseline.” Direct costs only were considered in the study (medical costs assuming that all patients received treatment for both eyes, physician services, VF testing, and IOP measure cost). Cost-effectiveness ratio of all interventions is declared in Table 5.

DISCUSSION

Results of this study demonstrate that bimatoprost significantly decrease IOP when compared with timolol or brimonidine while no clinically meaningful difference could be determined on comparing timolol and brimonidine.

This was in consistence with results of some other studies which stated that bimatoprost significantly decrease IOP[9-11] and those which stated that topically applied twice daily for 1 month, brimonidine tartrate 0.2% has clinical effectiveness equivalent to timolol 0.5% in Taiwanese patients with glaucoma.[12]

In contrast to results of this study was that done by Araie et al. which stated that topical brimonidine showed a significant IOP-lowering effect, although its IOP-lowering effect was inferior to topical timolol as monotherapy.[13]

Concerning cost-effectiveness this study revealed that timolol is more dominant than bimatoprost and brimonidine. This was in consistence with results of the study by Rylander and Vold.[14]
In contrast to that was results obtained by van Gestel et al. which stated that initiation of monotherapy with a PG analog may be acceptable depending on the cost-effectiveness outcomes and reduction in the frequency of VF testing.\(^{[15]}\)

**CONCLUSION**

Treatment of open-angle glaucoma with any of used monotherapy is clinically effective. Although bimatoprost is most clinically effective treatment from the cost-effectiveness view, it would be preferable to initiate treatment with timolol in case of absence of any contraindications. PG analog can be used as add-on therapy in low responder patients or as alternative treatment in case of presence of contraindication to use of beta blockers.

**Financial support and sponsorship**

Nil.

**Conflict of interest**

There are no conflicts of interest.

**REFERENCES**

1. Daka Q, Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: An overview of reviews. Croat Med J 2014;55:468-80.
2. King A, Azuara-Blanco A, Tuulonen A. Glaucoma. BMJ 2013;346:f3518.
3. Tataru CP, Purcarea VL. Antiglaucoma pharmacotherapy. J Med Life 2012;5:247-51.
4. van Gestel A, Schouten JS, Beckers HJ, Severens JL, Hendrikse F, Webers CA. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension. Acta Ophthalmol 2014;92:513-23.
5. Aydin Kurna S, Acikgoz S, Altun A, Ozbay N, Sengor T, Olcaysu OO. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: A prospective study. J Ophthalmol 2014;2014:460483.
6. Schlote T. Mode of action, clinical profile and significance of beta-blockers in antiglaucoma therapy. Klin Monbl Augenheilkd 2013;230:120-6.
7. Yu A, Welge-Lüssen U. Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy. Klin Monbl Augenheilkd 2013;230:127-32.
8. Hirsch JD, Morello C, Singh R, Robbins SL. Pharmacoeconomics of new medications for common chronic ophthalmic diseases. Surv Ophthalmol 2007;52:618-33.
9. Wang K, Xu L, Yuan Z, Yao K, Zhao J, Xu L, et al. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China. BMC Ophthalmol 2014;14:21.
10. Berenson KL, Kymes S, Hollander DA, Fiscella R, Burk C, Patel VD. Cost-offset analysis: Bimatoprost versus other prostaglandin analogues in open-angle glaucoma. Am J Manag Care 2011;17:e365-74.
11. Frenkel RE, Frenkel M, Toler A. Pharmacoeconomic analysis of prostaglandin and prostaamide therapy for patients with glaucoma or ocular hypertension. BMC Ophthalmol 2007;7:16.
12. Chen MJ, Chou JC, Hsu WM, Liu JH. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: A randomized clinical trial on Taiwanese patients. J Chin Med Assoc 2003;66:276-81.
13. Araie M, Yamazaki Y, Sugiyama K, Kuwayama Y, Tanihara H. Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension–Comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy. Nippon Ganka Gakkai Zasshi 2012;116:955-66.
14. Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J Ophthalmol 2008;145:106-13.
15. van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, et al. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol 2012;90:20-31.